BofA IG Healthcare Weekly: Vital Signs

Research evidence excerpt

BofA IG Healthcare Weekly: Vital Signs

Accessible version

BofA IG Healthcare Weekly

Vital Signs

Industry Overview

Healthcare Highlights: ABBV, BIIB, PFE, LLY 22 June 2026

S&P revised its outlook on AbbVie to positive from stable. Biogen announced the High Grade Credit

acquisition of RayThera for up to $1 billion, consisting of an upfront payment and United States

milestones, with an expected close in the third quarter of this year. The deal includes Healthcare

multiple anti-inflammatory assets that could treat immune-mediated conditions across a Andrew Kaplan

range of indications. Pfizer announced that Dave Denton, Chief Financial Officer, will step Research Analyst

down on August 15. Denton will pursue a professional opportunity outside of the BofAS+1 646 855 8748

pharmaceutical industry. The company has named Cecile Guegan, currently Senior Vice andrew.kaplan@bofa.com

President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Vritika Patni

Research Analyst

Officer. Eli Lilly acquired 4E Therapeutics, a neuroscience company developing treatments BofAS

for chronic pain, for an undisclosed amount. +1 646 855 7042

vritika.patni@bofa.com

Healthcare outperformed the IG Index last week

The ICE BofA IG Healthcare index outperformed the ICE BofA IG index, at 0.12% versus

0.07% on a total-return basis. Healthcare Facilities led other subsectors, with a total

return of 0.25%. In Europe, Healthcare outperformed the ICE BofA EMU index, at Stock symbols and abbreviations

0.59% versus 0.47%. ABBV AbbVie

Avg Average

YTD, healthcare outperformed on total return BIIBLLY BiogenEli Lilly

YTD, IG Healthcare outperformed the ICE BofA IG index, at a total return of 1.13% versus OAS Option adjusted spread